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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
This review aims to look at the benefits and harms of CCB for people with CKD requiring dialysis.
B A C K G R O U N D
Chronic kidney disease (CKD) is a growing health concern as-
sociated with a high risk of adverse outcomes. Its prevalence is
increasing at a rate of 8% per year worldwide (Ruilope 2008).
The aetiology of CKD differs by region, age, gender and race. In
Europe, Japan and the United States, diabetic nephropathy is the
leading cause of CKD, while in the developing world, chronic
glomerulonephritis and systemic hypertension are the leading
causes (Ruilope 2008). Hypertension as a complication is highly
prevalent in patients who have end-stage kidney disease (ESKD).
In India, a population based study determined the crude and age
adjusted ESKD rates were 151 and 232 per million population,
respectively. The number of patients requiring dialysis in India is
estimated to be 55,000 with an annual growth rate of between 10
and 20% (Jha 2013).
Data from the South African dialysis and transplant registry
(SADTR) showed that hypertension was the cause of ESKD in
45.6% of 1549 patients in the year 1994 (Naicker 2003). In
Kenya, studies revealed a prevalence of hypertension ranging be-
tween 61.5% and 76% among patients with varying degrees of
CKD (Maritim 2007; Nadeem 2003; Rajula 2009) which illus-
trated the inadequacy of blood pressure control in this popula-
tion. It is imperative therefore to ensure adequate blood pressure
control in patients with ESKD requiring dialysis. This entails the
use of appropriate antihypertensives which will guarantee better
health outcomes.
Description of the condition
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CKD is defined as the progressive loss of renal function occurring
over several months to years and is characterized by the gradual
scarring of the kidney (Dipiro 2011). CKD is categorized by the
level of kidney function into stages 1 to 5 as proposed by the widely
accepted United States Kidney Disease Outcomes Quality Initia-
tive (K/DOQI); staging is determined by the glomerular filtration
rate (GFR) (Levey 2003).
The more recently published Kidney Disease Improving Guide-
lines Outcomes (KDIGO) 2012 clinical practice guidelines for
the evaluation and management of CKD have a slightly different
staging of CKD. They recommend that CKD be classified based
on the cause, GFR category and albuminuria category (CGA).
GFR categories are classified as G1, G2, G3a, G3b, G4 and G5
(Eknoyan 2013).
Data from the 1998 to 2004 national health and nutrition ex-
amination survey (NHANES) revealed a rise in the prevalence of
CKD. The prevalence rose in the above 20 age group from 14.5%
in the 1988 to 1994 NHANES to 16.8% in that survey (Onuigbo
2009). The more recent 2003 to 2006 survey has revealed an in-
crease in the prevalence of stage 3 CKD from 5.7% in the 1988 to
1994 study to 8.1%(Dipiro 2011). Reliable statistics for ESKDare
lacking in most African countries. It is however noted that CKD
is at least three to four times more prevalent in sub-Saharan Africa
than in more developed countries (Naicker 2003). The incidence
and prevalence of ESKD in North Africa is higher than in the
United States ranging between 34 and 200 per million (Barsoum
2003).
Description of the intervention
Calcium channel blockers (CCB) are antihypertensive agents
which act on both myocardial cells as well as on blood vessels.
They are classified broadly as either dihydropyridine or non-di-
hydropyridine types. The dihydropyridine CCB include nifedip-
ine which is the prototype within this group. Other agents in
this group are amlodipine, felodipine, isradipine, nicardipine, ni-
modipine, nitrendipine, nisoldipine, and efonipidine. The non-
dihydropyridine subclass includes diltiazem and verapamil which
are the prototypes for the benzothiazepine and phenylalkylamine
class of CCB (Hart 2008). Other agents include gallopamil and
bedipril.
How the intervention might work
CCB can be described as a heterogeneous group of compounds
that exhibit unique structures and pharmacological properties.
Their ability to lower blood pressure can be attributed to the fact
that all CCB are vasodilators. This vasodilatory ability is not equal
across all classes, with the dihydropyridines being more potent va-
sodilators than the non-dihydropyridines (Sica 2005).
The two classes of CCB inhibit two types of voltage dependent
channels; a high voltage activated calcium channel including P/
Q, L, N, and R type channels, and low voltage activated T type
channel (Hart 2008). By preferentially binding onto the L types of
channels in the vasculature, dihydropyridine CCB cause vasodi-
latation with the subsequent drop in blood pressure. The non-
dihydropyridine CCB on the other hand bind preferentially onto
L type channels in the cardiac muscles, more so on the sino-atrial
node and the atrio ventricular node, causing negative chronotropic
effects and also decreasing activity of the sympathetic nervous sys-
tem. These effects all cause a decrease in blood pressure (Basile
2004).
Why it is important to do this review
Most patients undergoing dialysis are usually comorbid with hy-
pertension that is difficult to control and contributes to increased
cardiovascular morbidity and mortality (Inrig 2010; Van Buren
2012). The reported prevalence of hypertension indialysis patients
was 86% in an American cohort of 2535 clinically stable, adult
dialysis patients. Within that cohort, only 30% had adequately
controlled blood pressure (Agarwal 2003). Drugs used prior to de-
velopment of ESKD may not be a viable option thereafter. Some
drugs are dialyzable and their use would result in a rise in blood
pressure during dialysis (Inrig 2010; Van Buren 2012). Health
care workers are therefore faced with the challenge of choosing an
appropriate therapy for controlling blood pressure in ESKD pa-
tients undergoing dialysis. This choice needs be to evidence-based
hence the need for this review.
O B J E C T I V E S
This review aims to look at the benefits and harms of CCB for
people with CKD requiring dialysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs
in which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) looking at the effects of CCB on blood pressure control
in patients with CKD undergoing dialysis. The minimum study
duration should be 12 weeks.
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Types of participants
Inclusion criteria
All patients with CKD requiring dialysis (stage 5 as defined by
the K/DOQI guidelines (Levey 2003) or stage G5 as defined by
theKDIGO guidelines (Eknoyan 2013)).We will include patients
who undergo either haemodialysis or peritoneal dialysis. There
will be no restrictions on age, gender or race.
The participants will be comorbid with hypertension as defined by
the seventh report of the joint national committee on prevention,
detection, evaluation and treatment of high blood pressure (JNC
VII) (Chobanian 2003). Participants with or without diabetes (ei-
ther type 1 or 2) will be included. Patients with heart failure as
classified by the New York Heart Association (NYHA) stages I to
IV and angina will be included.
Exclusion criteria
Kidney transplant patients and patients with CKD stages 1 to
4 and stages G1 to G4 as per the K/DOQI guidelines (Levey
2003) and KDIGO guidelines (Eknoyan 2013) respectively will
be excluded.
Types of interventions
Any type of CCB compared with other antihypertensives or
placebo will be included. Four intervention types will therefore be
assessed as follows.
1. Dihydropyridine CCB versus placebo
2. Non-dihydropyridine CCB versus placebo
3. Dihydropyridine CCB versus other antihypertensives
4. Non-dihydropyridine CCB versus other antihypertensives.
The reviewwill be amended as newer drugs that have been licensed
become available. All drugs should be administered orally. The
dosages will be those that are required for control of hypertension
or appropriately adjusted dosages for reduced GFR and dialysis.
Combination preparations with other antihypertensives other
than CCB will not be included.
Types of outcome measures
Primary outcomes
1. Cardiovascular mortality
2. Pre-dialysis blood pressure levels
3. Occurrence of intradialytic hypotension.
Secondary outcomes
1. Incidence of other adverse events (reflex tachycardia,
headache, constipation, bradycardia and heart block, myocardial
infarction) related to the interventions
2. Cost: total healthcare costs.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Renal Group’s Specialised Register
through contact with the Trials Search Co-ordinator using search
terms relevant to this review. The Cochrane Renal Group’s Spe-
cialised Register contains studies identified from the following
sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts are available in the ’Specialised
Register’ section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors, who
will discard studies that are not applicable, however studies and
reviews that might include relevant data or information on trials
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will be retained initially. Two authors will independently assess
retrieved abstracts and, if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria. The two
authors will compare their lists and any differences in opinion
between the two authors will be resolved by discussion and, where
this fails, by arbitration by a third author.
Data extraction and management
Data extraction will be carried out independently by two authors
using standard data extraction forms. Studies reported in non-En-
glish language journals will be translated before assessment.Where
more than one publication of one study exists, reports will be
grouped together and the publication with themost complete data
will be used in the analyses. Where relevant outcomes are only
published in earlier versions these data will be used. Any discrep-
ancy between published versions will be highlighted. Differences
in opinion on data collection will be resolved by discussion and
where this fails by arbitration by a third author.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
An assessment of ’low risk’, ’high risk’ or ’unclear risk’ will be made
for each of the items based on the risk of bias tool (Appendix 2).
Two authors will compare the results and discuss any differences
in opinion. Any disagreements will be settled by a third author.
Measures of treatment effect
For dichotomous outcomes (e.g. death, adverse events such as
hypotension, cardiovascular morbidity) results will be expressed
as risk ratio (RR) with 95% confidence intervals (CI). Where
continuous scales of measurement are used to assess the effects
of treatment (blood pressure, quality of life), the mean difference
(MD) will be used, or the standardised mean difference (SMD)
if different scales have been used. If some studies have reported
change from baseline scores, these will be meta-analysed together
with studies reporting final value scores using the mean difference
method. In this case, if standard deviations of the changes are not
reported, they will be imputed as described in Chapter 16 of the
Cochrane Handbook (Higgins 2011). Studies reporting time to
event of outcomes as hazard ratios and confidence intervals will be
meta-analysed together with studies reporting risk ratios as long
as the proportional hazards assumption is reasonable. Otherwise,
these studies will be analysed as dichotomous data.
Unit of analysis issues
We do not foresee the use of non-standard design studies such as
cross-over trials and cluster-RCTs will be included in the review.
However, multiple arm studies may be found and included. In
such cases, all intervention groups that are relevant to the review
will be included.
Dealing with missing data
Any further information required from the original author will
be requested by written correspondence (e.g. emailing the corre-
sponding author) and any relevant information obtained in this
manner will be included in the review. Evaluation of important
numerical data such as screened, randomised patients as well as
intention-to-treat (ITT), as-treated and per-protocol (PP) popula-
tion will be carefully performed. Attrition rates, for example drop-
outs, losses to follow-up and withdrawals will be investigated. Is-
sues of missing data and imputation methods (for example, last-
observation-carried-forward (LOCF)) will be critically appraised
(Higgins 2011).
Assessment of heterogeneity
Statistical heterogeneity will be evaluated by visually inspecting
the forest plots to detect overlapping CIs, applying the Chi² test
(P value < 0.10 considered statistically significant), and also by
using the I² statistic where an I² of greater than 75% will be used
to represent substantial heterogeneity.
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers.
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Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be used to explore possible sources of
heterogeneity (e.g. participants, interventions and study quality).
Heterogeneity among participants could be related to age, gender,
ethnicity/race, renal pathology, type of dialysis and co-morbidities
(CVD, hypertension, diabetes mellitus). Heterogeneity in treat-
ments could be related to prior agents used and the agent, dose and
duration of therapy. Adverse effects will be tabulated and assessed
with descriptive techniques, as they are likely to be different for
the various agents used. Where possible, the risk difference with
95% CI will be calculated for each adverse effect, either compared
to no treatment or to another agent.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size:
• repeating the analysis excluding unpublished studies;
• repeat the analysis excluding studies with high risk of bias;
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results;
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. renal replacement therapy:ti,ab,kw
2. dialysis:ti,ab,kw
3. h*emodialysis:ti,ab,kw
4. h*emodiafiltration*:ti,ab,kw
5. h*emofiltration*:ti,ab,kw
6. (CAPD or CCPD or APD):ti,ab,kw
7. (“endstage kidney” or “endstage renal” or “end-stage kidney” or “end-stage renal”):ti,ab,kw
8. (ESKD or ESRD or ESKF or ESRF):ti,ab,kw
9. (“chronic kidney” near/2 (“stage 5” or “stage V”)):ti,ab,kw
10. {or #1-#9}
11. MeSH descriptor: [Calcium Channel Blockers] explode all trees
12. amlodipine:ti,ab,kw
13. barnidipine:ti,ab,kw
14. diltiazem:ti,ab,kw
15. felodipine:ti,ab,kw
16. flunarizine:ti,ab,kw
17. gallopamil:ti,ab,kw
18. isradipine:ti,ab,kw
19. lercanidipine:ti,ab,kw
20. manidipine:ti,ab,kw
21. nicardipine:ti,ab,kw
22. nifedipine:ti,ab,kw
23. nimodipine:ti,ab,kw
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(Continued)
24. nisoldipine:ti,ab,kw
25. nitrendipine:ti,ab,kw
26. verapamil:ti,ab,kw
27. calcium channel block*:ti,ab,kw
28. (CCB or CCBs):ti,ab,kw
29. {or #11-#28}
30. {and #10, #29}
MEDLINE 1. exp Renal Dialysis/
2. exp Hemofiltration/
3. Kidney Failure, Chronic/
4. dialysis.tw.
5. (hemodialysis or haemodialysis).tw.
6. (hemofiltration or haemofiltration).tw.
7. (hemodiafiltration or haemodiafiltration).tw.
8. (CAPD or CCPD or APD).tw.
9. (end-stage kidney or end-stage renal or endstage kidney or endstage renal).tw.
10. (ESKD or ESKF or ESRD or ESRF).tw.
11. (chronic kidney adj2 (stage 5 or stage V)).tw.
12. or/1-11
13. exp Calcium Channel Blockers/
14. amlodipine.tw.
15. barnidipine.tw.
16. diltiazem.tw.
17. felodipine.tw.
18. flunarizine.tw.
19. gallopamil.tw.
20. isradipine.tw.
21. lercanidipine.tw.
22. manidipine.tw.
23. nicardipine.tw.
24. nifedipine.tw.
25. nimodipine.tw.
26. nisoldipine.tw.
27. nitrendipine.tw.
28. verapamil.tw.
29. calcium channel block*.tw.
30. (CCB or CCBs).tw.
31. or/13-30
32. and/12,31
EMBASE 1. exp Renal Replacement Therapy/
2. (hemodialysis or haemodialysis).tw.
3. (hemofiltration or haemofiltration).tw.
4. (hemodiafiltration or haemodiafiltration).tw.
5. dialysis.tw.
6. (CAPD or CCPD or APD).tw.
7. Chronic Kidney Disease/
8. Kidney Failure/
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(Continued)
9. Chronic Kidney Failure/
10. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
11. (ESRF or ESKF or ESRD or ESKD).tw.
12. (chronic kidney adj2 (stage 5 or stage V)).tw.
13. or/1-12
14. exp calcium channel blocking agent/
15. calcium channel block*.tw.
16. (CCB or CCBs).tw.
17. amlodipine.tw.
18. barnidipine.tw.
19. diltiazem.tw.
20. felodipine.tw.
21. flunarizine.tw.
22. gallopamil.tw.
23. isradipine.tw.
24. lercanidipine.tw.
25. manidipine.tw.
26. nicardipine.tw.
27. nifedipine.tw.
28. nimodipine.tw.
29. nisoldipine.tw.
30. nitrendipine.tw.
31. verapamil.tw.
32. or/14-31
33. and/12,32
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
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(Continued)
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
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reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
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High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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